SRC-3 Has a Role in Cancer Other Than as a Nuclear Receptor Coactivator

Int J Biol Sci. 2011;7(5):664-72. doi: 10.7150/ijbs.7.664. Epub 2011 May 24.

Abstract

Steroid receptor coactivator-3 (SRC-3), also known as AIB1, is a member of the p160 steroid receptor coactivator family. Since SRC-3 was found to be amplified in breast cancer in 1997, the role of SRC-3 in cancer has been broadly investigated. SRC-3 initially was identified as a transcriptional coactivator for nuclear receptors such as the estrogen receptor (ER), involved in the proliferation of hormone-dependent cancers. However, increasing clinical evidence shows that dysregulation of SRC-3 expression in several human hormone-independent cancers is correlated with pathological factors and clinical prognosis. Recently, both in vivo and in vitro studies demonstrate that SRC-3 may influence a number of cancer cellular processes in several ways independent of nuclear receptor signaling. In addition, an SRC-3 transgenic mice model shows that SRC-3 induces tumors in several mouse tissues. These results indicate that the role of SRC-3 in cancer is not just as a nuclear receptor coactivator. The focus of this review is to examine possible SRC-3 roles in cancer, other than as a nuclear receptor coactivator.

Keywords: Steroid receptor coactivator-3; apoptosis; cell cycle; invasion and metastasis; mice model; tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Apoptosis / physiology
  • Cell Cycle / genetics
  • Cell Cycle / physiology
  • Cell Proliferation
  • Humans
  • Mice
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Nuclear Receptor Coactivator 3 / genetics
  • Nuclear Receptor Coactivator 3 / metabolism*
  • Nuclear Receptor Coactivators / genetics
  • Nuclear Receptor Coactivators / metabolism*

Substances

  • Nuclear Receptor Coactivators
  • Nuclear Receptor Coactivator 3